Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

both locally and in distant sites in the body.  This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeated.  Normal cells are not affected by JX-594 resulting in safety and tolerability.

The poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program.  This strain naturally targets cancer cells due to common genetic defects in cancer cells.  JX-594 was engineered to enhance this natural safety and cancer-selectivity by deleting its thymidine kinase (TK) gene, thus making it dependent on the cellular TK expressed at persistently high levels in cancer cells.  To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein.  GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attack.

About Jennerex

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.  The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers.  Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells.  These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut off the blood supply to tumors, as well as stimulating the body's immune response to the cancer.  Jennerex, Inc. is headquartered in

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... advanced cell culture products, announces the availability of BI’s line of human mesenchymal ... Industries, these stem cell differentiation media offer a complete system for multipotency evaluation ...
(Date:7/28/2015)... ... ... new Xsample 530 sample changer for vials can be used with Anton Paar ... less than 12,000 mPas (internal air) up to 36,000 (external air) – and can process ... about Xsample 530 is its removable magazine, which is easily lifted off its hub and ...
(Date:7/28/2015)... July 21, 2015 ... the addition of the "Analysis of the ... their offering. Globally, flow cytometry remains ... cell proliferation, cancer, and stem cells. But the ... primarily because of demand from underdeveloped nations to ...
(Date:7/28/2015)... , July 28, 2015  Kerastem Technologies announce that ... the U.S. FDA Center For Biologics Evaluation and Research ... conduct a clinical trial investigating the safety and feasibility ... and early male pattern baldness (androgenic alopecia). ... follows initial clinical work in Europe ...
Breaking Biology Technology:Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3New Moves in Automatic Sample Handling: Introducing Xsample 530 2Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2
... , ... Director, Clinical Services, will lead a panel of life sciences executives on the topic ... center around risk/reward approaches and technology collaboration among clinical trial sponsors and service providers ... ...
... COPENHAGEN, July 14 When world political leaders are ... Climate Change Conference in December 2009, environmentally friendly fuel ... Biofuels, a co-operation between Danisco,s biotech division Genencor, Inbicon, ... generation bioethanol for 40 of the cars that the ...
... ... ... July 14, 2009 -- Quantros, a leading provider of safety and quality software and ... Hospital and USC Kenneth Norris, Jr. Cancer Hospital at the University of Southern California. ...
Cached Biology Technology:ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 2ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 3Politicians to Drive on Straw-Based Bioethanol at the Climate Change Conference 2Politicians to Drive on Straw-Based Bioethanol at the Climate Change Conference 3USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk 2USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk 3
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
(Date:7/7/2015)... June 30, 2015 ... the addition of the "Capacitive Fingerprint Sensors ... To this date, fingerprint sensing technology is ... fingerprint sensors are well developed. This patent landscape ... The domain of capacitive fingerprint sensors ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... researchers have devised a way to use a brief burst ... gold launch pad. The technique could someday be used to ... implanted in the body. The method also may be useful ... small quantities of a material. , The technique was described ...
... the Neanderthal genome, scientists suggest an early human-Neanderthal split. ... authors, but do not share much else after evolving ... issue of Science, also finds no evidence of genetic ... to explain the evolutionary relationship between Homo sapiens and ...
... DNA may not hold the key to your origins ... access journal BMC Biology reveals that fewer than 10% ... matched to mitochondrial DNA from one single African ethnic ... use of mitochondrial DNA to trace maternal ancestries, and ...
Cached Biology News:Electric jolt triggers release of biomolecules, nanoparticles 2Genetic study of Neanderthal DNA reveals early split between humans and Neanderthals 2Genetic study of Neanderthal DNA reveals early split between humans and Neanderthals 3
Anti-Protein Kinase-A (PKA) Regulatory subunit IIB; rabbit host...
... This protein is a member of the ... Members of the PAX family typically contain ... homeodomain. These proteins play critical roles during ... 3 are associated with Waardenburg syndrome, craniofacial-deafness-hand ...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
... in collaboration with Pall Life Sciences to ... a variety of membrane chemistries. The Automation ... the Caliper TPWII, MultiDose, Prelude, and Benchmate ... Automation Certified Syringe Filters are available at ...
Biology Products: